ClinicalTrials.gg
Active, not recruitingNCT04482595Updated Oct 1, 2024

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

A Phase 2 interventional study of BIO 300 Oral Suspension and Placebo in COVID-19, Long COVID and Pulmonary Fibrosis, sponsored by Humanetics Corporation. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Humanetics Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
81st of 155
50 · median 52
Started
2020
with 5 others
Phase 2
47 of 194
10 open now
Primary completion
2024-07
later than 1 of 83 live
Registered
2nd of 194
by date

Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 81st largest by planned enrollment of the 155 interventional ones that give a count, is one of 6 that started in 2020, is one of 47 in phase 2, reaches primary completion later than 1 of the 83 other live ones, and was the 2nd registered.

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.

03

Conditions studied

  • COVID-19
  • Long COVID
  • Pulmonary Fibrosis
  • Post-acute Respiratory Complications of COVID-19

Browse trials for

04

In context

Post-Acute COVID-19 Syndrome Reclassified

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18
  2. Patients hospitalized for COVID-19-related complications ready to be discharged and those within 365 days of discharge (even if the patient was referred to subacute or acute respiratory rehabilitation after discharge)
  3. Radiographic signs of lung injury after standard treatment of COVID-19 such as, ground glass opacity, consolidation, or fibrotic shadows at screening
  4. Able to perform a PFT and have a DLCO \<70% of predicted at screening
  5. Able to perform a 6-minute walk test
  6. Blood routine, liver and kidney function test values are within the controllable range

    1. Adequate hepatic function as evidenced by , AST and LDH \< 2X and \< 1.5X ULN for the reference lab
    2. Adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for the reference laboratory OR a calculated of ≥ 60 mL/min by the Cockcroft-Gault Equation
    3. Adequate hematopoietic function as evidenced by white blood cells ≥ 3x10\^9 / L and ≥ 100x10\^9 / L
  7. Female patients of must have a negative pregnancy test at screening
  8. Female patients of childbearing potential and male participants with female sexual partners of childbearing potential must agree to use an effective method of non-estrogen-based (e.g., condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill) during the 12-week portion of the study that they are receiving study medication and for 30 days following the last dose of study medication, or to abstain from sexual intercourse during these time periods. Women who have been off estrogen contraceptives for a minimum of 5 days prior to the first scheduled day of study intervention dosing are eligible. A woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is , defined as no menstrual periods for 12 consecutive months
  9. Ability of the patient or the patient's legal representative to read and provide written

Exclusion criteria

Exclusion Criteria:

  1. Severe background disease like severe cardiac or pulmonary insufficiency (WHO grade III or IV), severe liver and kidney diseases, severe , severe neurological disease, or concurrent (other than non-melanoma skin cancer) which is uncontrolled or actively being treated
  2. Severe asthma on chronic therapy with biologics or .
  3. Prior malignancy in which any thoracic radiotherapy was administered except for partial or tangent breast irradiation for early-stage (stages I or II) breast cancer
  4. D-dimer levels of >2,000 ng/mL at screening
  5. Use of anti-pulmonary fibrosis drugs (e.g., imatinib, nintedanib, pirfenidone, penicillamine, colchicine, tumor necrosis factor alpha blocker) within 5 days of the first scheduled day of study intervention dosing
  6. Use of anti-cytokine release syndrome drugs (e.g., anakinra, sarilumab, siltuximab, tocilizumab and/or lenzilumab) within 5 days of the first scheduled day of study intervention dosing
  7. Use of systemic corticosteroids (e.g., prednisone, dexamethasone) within 5 days of the first scheduled day of study intervention dosing
  8. An active infection or infection with a fever ≥ 38.5°C within 3 days of the first scheduled day of study intervention dosing
  9. Poorly controlled intercurrent illnesses, such as interstitial lung disease, uncontrolled hypertension; poorly controlled diabetes mellitus; unstable angina, myocardial infarction, acute coronary syndrome or cerebrovascular event within 6 months of Screening; history of congestive heart failure ( Class III or IV); severe valvular heart disease; or poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker
  10. with Fridericia's correction that is unmeasurable, or ≥480 msec on screening . The average QTc from the screening ECG (completed in triplicate) must be \<480 msec for the patient to be eligible for the study
  11. Patients taking any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes (www.crediblemeds.org) are not eligible if QTc ≥460 msec
  12. Patients who have undergone thoracotomy within 4 weeks of Day 1 of protocol therapy
  13. Patients that have a known allergy to any of the placebo components
  14. Psychiatric conditions, social situations or substance abuse that precludes the ability of the study participant to cooperate with the requirements of the trial and protocol therapy
  15. Pregnancy or currently on estrogen-based
  16. Women who are breastfeeding
  17. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BIO 300 Oral Suspension (genistein 1500 mg)

    BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.

    Drug: BIO 300 Oral Suspension

  • Placebo comparator
    Placebo

    BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.

    Drug: Placebo

Interventions

  • Suspension of genistein nanoparticles

  • DrugPlacebo

    Matched placebo for BIO 300 Oral Suspension

07

What researchers measure

Primary outcomes

  1. Change in DLCO

    Diffusing capacity of the lungs for carbon monoxide (DLCO)

    Time frame: 12 Weeks

Secondary outcomes

  1. Change in 6 Minute Walk Test

    6 minute walk test (6MWT)

    Time frame: 12 Weeks

  2. Change in FVC

    Forced vital capacity (FVC)

    Time frame: 12 Weeks, 6 Months and 12 Months

  3. Change in St. George's Respiratory Questionnaire (SGRQ) Scores

    Patient reported outcome to measure impact on overall health, daily life, and perceived well-being in patients with impaired pulmonary function. Scores range from 0-100 with higher scores indicating more limitations.

    Time frame: 12 Weeks, 6 Months and 12 Months

  4. Change in Pulmonary Fibrosis on HRCT Scan

    Evidence of pulmonary fibrosis on high resolution computerized tomography (HRCT) scans of the lungs based on a 4-point Likert scale, where 0 is no evidence of fibrosis and 3 is severe fibrosis

    Time frame: 12 Weeks, 6 Months and 12 Months

  5. Incidence of Re-Hospitalization

    Incidence of hospitalization after initial discharge and initiating treatment

    Time frame: 12 Months

  6. All-Cause Mortality

    Mortality at 12 months after initiating treatment

    Time frame: 12 Months

  7. Change in FEV1

    Forced expiratory volume in one second (FEV1)

    Time frame: 12 Weeks, 6 Months and 12 Months

  8. Change in FEV1/FVC Ratio

    Ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC)

    Time frame: 12 Weeks, 6 Months and 12 Months

  9. Change in 6 Minute Walk Test

    6 minute walk test (6MWT)

    Time frame: 6 Months and 12 Months

  10. Change in Pulse Oximetry at Rest and During the 6MWT

    Oxygen saturation (pulse oximetry) at rest and during the 6 minute walk test (6MWT)

    Time frame: 12 Weeks, 6 Months and 12 Months

  11. Change in DLCO

    Diffusing capacity of the lungs for carbon monoxide (DLCO)

    Time frame: 6 Months and 12 Months

  12. Adverse Events Related to BIO 300 Oral Suspension

    Evaluate the safety of BIO 300 Oral Suspension treatment

    Time frame: 12 Months

  13. Change in Clinical Laboratory Values

    Monitoring of blood serum levels for bilirubin, C-reactive protein (CRP), creatinine, blood urea nitrogen (BUN), cholesterol and triglycerides (all reported as mg/dL)

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

  14. Change in Clinical Laboratory Values

    Monitoring of blood serum levels for troponin T, d-dimer and ferritin (all reported as ng/mL)

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

  15. Change in Clinical Laboratory Values for Albumin

    Monitoring of blood serum levels for albumin (g/dL)

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

  16. Change in Clinical Laboratory Values for Serum Enzymes

    Monitoring of blood serum levels for alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) (all reported as Units/L)

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

  17. Change in Complete Blood Counts with Differential

    Monitoring of white blood cell, red blood cell and platelet counts

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Other outcomes

  1. Change in Supplemental Oxygen Use

    Prescribed supplemental oxygen flow rate at night, rest and exertion

    Time frame: 12 Weeks, 6 Months and 12 Months

  2. Change in Duration of Supplemental Oxygen Use

    Duration of supplemental oxygen use

    Time frame: 12 Weeks, 6 Months and 12 Months

  3. Change in Serum Cytokine Expression

    Expression levels of serum-derived cytokines (IL-1b, IL-6, IL-8, TNFa, and TGFb1)

    Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

08

Study locations

4 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2024, 44 months.

Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 22, 2020
StartActual
Nov 11, 2020
Primary completionActual
Jul 31, 2024
CompletionEst.
Apr 30, 2025
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04482595
Lead sponsor
Humanetics Corporation
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Nov 11, 2020
Primary completion
Jul 31, 2024
Completion
Apr 30, 2025 (estimated)
Last update
Oct 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Genistein-based BIO 300

Start the discussion